Clinical Trial: Treatment of Patients With Advanced Solid Tumors Using CRTKVA11-03 TCR-T Cell Injection

U.S., Sept. 18 -- ClinicalTrials.gov registry received information related to the study (NCT07826585) titled 'Treatment of Patients With Advanced Solid Tumors Using CRTKVA11-03 TCR-T Cell Injection' on Sept. 09.

Brief Summary: This is a single-center, open-label, single-arm, dose-escalation study aimed at evaluating the safety and preliminary efficacy of KRAS-specific autologous TCR-T cells in patients with advanced solid tumors harboring KRAS G12V mutation.

Study Start Date: March 26

Study Type: INTERVENTIONAL

Condition: Advanced Solid Tumors

Intervention: DRUG: CRTKVA11-03 TCR-T Cell Injection

Drug1 : Fludarabine + Cyclophosphamide Drug2 :Interleukin 2 Drug3 :CRTKVA11-03 TCR-T Cell Injection

Recruitment Status: ACTIVE_NOT_RECRUIT...